Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q4 FY20 results · Jan–Mar 2020
Glenmark Pharmaceuticals reported revenue from operations of ₹2,767.49 crore (up 8.0% from Q4 FY19) and net profit of ₹220.31 crore (up 36.3% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,767.49 | 2,563.47 | +8.0% | 2,735.56 | +1.2% |
| Other income | 44.15 | 39.06 | +13.0% | 32.96 | +33.9% |
| Total income | 2,811.63 | 2,602.53 | +8.0% | 2,768.52 | +1.6% |
| Profit before tax | 317.96 | 240.31 | +32.3% | 270.98 | +17.3% |
| Net profit for the period | 220.31 | 161.66 | +36.3% | 190.84 | +15.4% |
| EPS, basic (₹) | 7.81 | 5.73 | +36.3% | 13.52 | not comparable |
| Net margin (%) | 8.0 | 6.3 | 7.0 |
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,607.73 | 1,587.28 | +1.3% | 1,816.29 | −11.5% |
| Other income | 251.29 | 168.39 | +49.2% | 94.49 | +165.9% |
| Total income | 1,859.02 | 1,755.67 | +5.9% | 1,910.78 | −2.7% |
| Profit before tax | 372.55 | 358.18 | +4.0% | 410.64 | −9.3% |
| Net profit for the period | 349.19 | 281.29 | +24.1% | 345.53 | +1.1% |
| EPS, basic (₹) | 12.38 | 9.97 | +24.2% | 24.50 | not comparable |
| Net margin (%) | 21.7 | 17.7 | 19.0 |
Consolidated
- Filed with BSE
- 27 Jun 2020, 18:33 IST
- Board meeting
- 26 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jun 2020, 18:33 IST
- Board meeting
- 26 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE